Literature DB >> 17442557

Apoptosis induced by the lymphocyte effector molecule perforin.

Paul Bolitho1, Ilia Voskoboinik, Joseph A Trapani, Mark J Smyth.   

Abstract

Recent progress has been made in discovering structure/function relationships of the cytotoxic lymphocyte pore-forming protein - perforin - and its role in immune regulation. Long recognized as a key component of the granule exocytosis mechanism of lymphocyte-mediated apoptosis and in host defence against a variety of pathogens and tumors, more recent attention has focused upon mutations of the perforin gene in some patients with hemophagocytic lymphohistiocytosis. This clinical picture has prompted further work to uncover the molecular structure of perforin and to define its precise role in immune regulation and immunopathology.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17442557     DOI: 10.1016/j.coi.2007.04.007

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  43 in total

1.  Perforin activity at membranes leads to invaginations and vesicle formation.

Authors:  Tilen Praper; Andreas F-P Sonnen; Ales Kladnik; Alberto O Andrighetti; Gabriella Viero; Keith J Morris; Emanuela Volpi; Lorenzo Lunelli; Mauro Dalla Serra; Christopher J Froelich; Robert J C Gilbert; Gregor Anderluh
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-15       Impact factor: 11.205

Review 2.  Living in a house of cards: re-evaluating CD8+ T-cell immune correlates against HIV.

Authors:  George Makedonas; Michael R Betts
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

3.  Regulation of perforin lysis: implications for protein disulfide isomerase proteins.

Authors:  David L Tamang; Bryce N Alves; Viki Elliott; Doug Redelman; Renu Wadhwa; Stephanie A Fraser; Dorothy Hudig
Journal:  Cell Immunol       Date:  2009-01-14       Impact factor: 4.868

4.  Memory CD8+ T cells specific for a single immunodominant or subdominant determinant induced by peptide-dendritic cell immunization protect from an acute lethal viral disease.

Authors:  Sanda Remakus; Daniel Rubio; Xueying Ma; Alessandro Sette; Luis J Sigal
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

Review 5.  Endolysosomal proteases and their inhibitors in immunity.

Authors:  Phillip I Bird; Joseph A Trapani; José A Villadangos
Journal:  Nat Rev Immunol       Date:  2009-12       Impact factor: 53.106

6.  Increased HIV-specific CD8+ T-cell cytotoxic potential in HIV elite controllers is associated with T-bet expression.

Authors:  Adam R Hersperger; Jeffrey N Martin; Lucy Y Shin; Prameet M Sheth; Colin M Kovacs; Gabriela L Cosma; George Makedonas; Florencia Pereyra; Bruce D Walker; Rupert Kaul; Steven G Deeks; Michael R Betts
Journal:  Blood       Date:  2011-02-02       Impact factor: 22.113

7.  Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection.

Authors:  Vitaly V Ganusov; Nilu Goonetilleke; Michael K P Liu; Guido Ferrari; George M Shaw; Andrew J McMichael; Persephone Borrow; Bette T Korber; Alan S Perelson
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

Review 8.  Perforin and granzymes: function, dysfunction and human pathology.

Authors:  Ilia Voskoboinik; James C Whisstock; Joseph A Trapani
Journal:  Nat Rev Immunol       Date:  2015-06       Impact factor: 53.106

Review 9.  T Cells and Regulated Cell Death: Kill or Be Killed.

Authors:  Johan Spetz; Adam G Presser; Kristopher A Sarosiek
Journal:  Int Rev Cell Mol Biol       Date:  2018-08-29       Impact factor: 6.813

10.  Perforin and IL-2 upregulation define qualitative differences among highly functional virus-specific human CD8 T cells.

Authors:  George Makedonas; Natalie Hutnick; Danielle Haney; Alexandra C Amick; Jay Gardner; Gabriela Cosma; Adam R Hersperger; Douglas Dolfi; E John Wherry; Guido Ferrari; Michael R Betts
Journal:  PLoS Pathog       Date:  2010-03-05       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.